Prothena Co. PLC (PRTA) Expected to Announce Quarterly Sales of $220,000.00

Equities analysts expect Prothena Co. PLC (NASDAQ:PRTA) to announce sales of $220,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Prothena’s earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $230,000.00. Prothena posted sales of $280,000.00 during the same quarter last year, which would indicate a negative year-over-year growth rate of 21.4%. The business is expected to announce its next earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Prothena will report full-year sales of $780,000.00 for the current fiscal year, with estimates ranging from $700,000.00 to $860,000.00. For the next fiscal year, analysts anticipate that the business will report sales of $48.45 million, with estimates ranging from $45.90 million to $51.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that follow Prothena.

Prothena (NASDAQ:PRTA) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.08. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.20 million. Prothena had a negative return on equity of 33.45% and a negative net margin of 13,978.88%.

Several equities research analysts have recently weighed in on the company. BidaskClub raised Prothena from a “hold” rating to a “buy” rating in a research report on Saturday, March 16th. Zacks Investment Research raised Prothena from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Wednesday, January 23rd. Finally, ValuEngine raised Prothena from a “sell” rating to a “hold” rating in a research report on Tuesday, April 23rd. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $12.26.

Prothena stock traded up $0.24 during trading hours on Thursday, reaching $9.52. 190,062 shares of the company were exchanged, compared to its average volume of 338,595. The stock has a market capitalization of $369.95 million, a P/E ratio of -2.64 and a beta of 2.40. The company has a quick ratio of 27.85, a current ratio of 27.85 and a debt-to-equity ratio of 0.07. Prothena has a 12 month low of $8.63 and a 12 month high of $15.91.

Several institutional investors and hedge funds have recently bought and sold shares of PRTA. Bank of America Corp DE boosted its position in shares of Prothena by 553.7% in the fourth quarter. Bank of America Corp DE now owns 529,262 shares of the biotechnology company’s stock valued at $5,451,000 after acquiring an additional 645,905 shares during the period. Morgan Stanley boosted its position in shares of Prothena by 581.8% in the first quarter. Morgan Stanley now owns 681,465 shares of the biotechnology company’s stock valued at $8,266,000 after acquiring an additional 581,519 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Prothena by 32.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,683,359 shares of the biotechnology company’s stock valued at $20,418,000 after acquiring an additional 410,527 shares during the period. Tang Capital Management LLC boosted its position in shares of Prothena by 580.2% in the first quarter. Tang Capital Management LLC now owns 323,823 shares of the biotechnology company’s stock valued at $3,928,000 after acquiring an additional 276,213 shares during the period. Finally, Norges Bank bought a new stake in shares of Prothena in the fourth quarter valued at approximately $2,212,000.

Prothena Company Profile

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.

See Also: Green Investing

Get a free copy of the Zacks research report on Prothena (PRTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.